INVESTOR PRESENTATION

May 2015

Medibio

Mission:
- To be the first FDA approved diagnostic for depression/anxiety and evaluation of treatment response
- Monetise our objective test for stress for the corporate workplace and App market

Vision:
- Early entrant in the transformation of Mental Health by technology (Digital Health)

Ripe for Disruption:
"It is critical to realise that we cannot succeed if we use DSM categories as the gold standard" - "We need a quantitative method for diagnosing depression" (U.S. National Institute of Mental Health - May 2013)

Strategic Partners:
- Johns Hopkins University and the Black Dog Institute
- World leaders in mental health research

BLACK DOG INSTITUTE
Because everyone deserves peace of mind

JOHNS HOPKINS
MEDICINE
SCHOOL OF MEDICINE

Valuation:
- Capitalisation A$30m
- 90M shares @ $0.33

Our 5 Year Goal:
- Workplace Stress market   US$100 million revenue
- Depression Diagnostic   US$60 million revenue
- Consumer App Market   tba

strong margins →

Significant Earnings

MENTAL HEALTH LANDSCAPE

350 Million Worldwide Diagnosed With Depression
1 Suicide Every 40 Seconds

1 Million Suicides
Every Year

26%
of Adult
Population

1 in 10 on Antidepressants
US $10Bn Spent annually

27%
of Adult
Population

20%
of Adult
Population

Global Cost US$2.5T (2030 est. US$6T) — Depression and Anxiety account for **+50%** of this burden

http://www3.weforum.org/docs
WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf

Convergence of 2 Huge Industries

Information Technology

- 4.3% of US GNP
- $700 billion

Healthcare

- 17.2% of US GNP
- $2.8 trillion

Digital Health

- Medibio is not revenue dependent upon regulatory approval

- The sole new and credible method for the diagnosing stress levels, easily translated to the workplace, wearable, and the App market

- This stress market can be accessed without regulatory approval

TIMELINE TO COMMERCIALISATION

Dec 14	Mar 15	Jun 15	Dec 15	Mar 16	Jun 16

| Johns Hopkins Study | US Validation Study | | Completion & Publication | FDA (approval Targeted within 12 months) | Anxiety Panic Disorder Study |

| Black Dog Study | Australian Validation Study | | Completion & Publication | FDA (approval Targeted within 12 months) | Anxiety Panic Disorder Study |

| Corporate Stress Product | Workplace Stress Product Development | Stress Product Launch | First Revenue |

THE PROBLEM

- No objective test for mental illness

- The diagnostic "gold standard" is a clinical/expert opinion

- Diagnostic agreement between clinicians can vary considerably

- Misdiagnosis of depression (and other mental illness) places a huge cost burden on the healthcare system and the workplace

THE SOLUTION

- Quantitative, objective test

- Diagnosis based on patient's biological data (circadian heart rate)

- Simple, safe, quick, and unobtrusive

- Gives objective indication of treatment effectiveness

- Savings to the health system

- MEB's technology based on over 15 years of research

- Different forms of mental illness such as anxiety and depression are associated with distinctly different patterns of CHR

- Distinct 'biomarkers' in heart rate data for depression and certain other mental illnesses

- CHR is 'state-dependent' - a change in clinical status is associated with a change in CHR patterns

- Serial monitoring of patients under psychiatric treatment showed that:

  - *effective intervention is associated with normalisation of CHR*
  - *ineffective intervention does not show normalisation*
  - *provides a tool for determining the treatment effectiveness*

- The autonomic nervous system (ANS) plays a key role in circadian sleep-wake regulation of physiological activity including heart rate

- Conventionally mental illness is associated with disturbances in ANS/circadian regulation

- Mental state-linked ANS disturbance is observed via the cardiovascular system, particularly during sleep when external influences are absent

- Analysis of CHR gives objective indications of 'core' physiological differences between broadly different forms of mental illness such as anxiety and depression and stress

JOHNS HOPKINS (JHU) STUDY OBJECTIVE

- To validate the use of Medibio's CHR technology to differentiate between depressed and non-depressed individuals
- Designed to provide clinical data to support FDA certification of Medibio's proprietary depression test

STUDY TIMELINE

- Anticipated results published in Q4 2015
- Simple, quick, powered to only need 80-100 participants

BLACK DOG INSTITUTE STUDY OBJECTIVE

- To demonstrate that CHR Technology distinguishes between melancholic and non-melancholic depression and also determine treatment response.

STUDY TIMELINE

- Anticipated results published in Q4 2015
- Simple, quick, powered to only need 60-80 participants

CLINICAL

NON-CLINICAL (Stress)

MEDICAL
(US$30Bn)

Primary Care Physicians

Psychiatrists

Psychologists

Therapists

Counsellors

Cardiologists

CORPORATE
(US$19Bn)

High Risk Occupations
- Defence
- Police
- Fire/Emergency

Insurance Companies

Corporate Wellness

Professions

Elite Sports

CONSUMER
(US$26Bn)

App Stores

Insurance Companies

Wellness

Digital Health

Companies

Clinician orders test

No disruption to normal clinical work flow

Secure access to Diagnostic Reporting and Analysis – Anywhere/Anytime

CHR collected from Patient and transmitted to HIPAA compliant Cloud Storage

CHR processed by machine learning algorithms Biometric data stored in HIPAA compliant cloud

- Revenue Model – (Pathology model whereby GP's refer the patients for the test)

  - 16 million annual GP visits in Australia for mental health
    - 63/100 prescribe/recommend psychotropic medications
    - 47/100 provide counselling
    - 7.4/100 refer to a psychologist & 1.9/100 refer to a psychiatrist

  - Initial diagnostic market – 16 million annual GP visits
    - @ $45 = $720 million annually

  - Treated market (ongoing monitoring) 1 million diagnosed with depression in Australia

- Identified a series of existing CPT™ codes and payment structures which are supportive of, and can likely be leveraged for, MEB's business plan in the US

Medicare		Private	Insurance	Assumption
93225	Recoding (Provider)	$26.87	$40	
93226	Analysis with Report (Medibio)	$37.97	$57	$45
93227	Physician review & Interpretation (Provider)	$26.87	$40	

- Cloud based analysis and reporting = minimal costs per report

Ametus Group Commercialization Study Feb 2015. Note these figures are for depression only

THE PRODUCT

- Stress leads to changes in autonomic regulation that are reflected in 'deviations' in CHR patterns
- MEB's technology provides an objective measure of the impact of stress on wellbeing
- Version 1 - Normal-Mild Stress, Moderate Stress, and Severe Stress

US MARKET

- 54 million employees in the US (+1,000 staff firms[2])
- 21.3 million US Government positions
- US$2.3Bn revenue potential annually

DEMAND IN THE US DRIVEN BY MANY FACTORS

- need to reduce health care spend
- social responsibility/OHS Requirements
- absenteeism, presenteeism (In a 3-month period, patients with depression miss an average of 4.8 workdays and suffer 11.5 days of reduced productivity[1])

1. US CDC, 2. US Census

- All current of the Apps related to stress/mental health are:

  - based on reducing tension via breathing, yoga, and relaxing sounds
  - wellness products not stress identification and management
  - mental health Apps are based on a digitised version of the DSM
  - none offer objective stress assessment based on extended research

- Medibio's App:

  - Based on 15 years of medical research which is currently being validated by Johns Hopkins University and Black Dog Institute
  - An objective, health sector endorsed, objective stress assessment application and management tool
  - Ability to compare this test with previous scans run to check progress
 - Best in class intervention tailored to your stress level

1. Source – Technology News.com.au
2. Accenture Digital Consumer Tech Survey 2014

Timing	Milestone	Status
Q4 2014	Australian and US validation studies (BDI & JHU)	✓
Q1 2015	Delivery of Commercialisation Study (AMETUS)	✓
	Establish World-Class Advisory Board (Dr Prendergast)	✓
Q2 2015	Acquire remaining patents covering the technology (USA/Canada)	✓
	Complete beta testing of Stress Algorithms and lodge patent applications	
	Strategic Device Partner	
	Announcement of foundation customers	
	Pre-submission package delivered to the FDA and FDA feedback	
Q3 2015	Complete development of Corporate Stress product	
	Commercial launch of Corporate Stress product	
Q4 2015	Results from US/Australian validation studies published	
	Commercial launch of Consumer Stress App (subject to device)	

New Stress and Diagnostic algorithms developed beta testing being completed

No data handling. Data transmitted direct to the cloud for cloud based processing

Johns Hopkins Hospital and Black Dog Institute.

SCALABLE

Strategic Device Partnership

Medical Market Assessment and Validation Study completed by (Ametus Group)

Developed

Opinion Leaders

Delivery Platform

Large Market

MEDIBIO

World leading Mental Health Diagnostics Service

Foundation customers for Corporate Stress Product

Revenue

Validation

FDA/TGA Submissions using NAMSA (Best in class regulatory consultants)

This presentation does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

Certain statements made in this presentation are forward-looking statements. These forward looking statements are not historical facts but rather are based on Medibio Limited's current expectations, estimates and projections about the industry in which Medibio operates, and its beliefs and assumptions.

Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered at-risk statements. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Medibio, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.

Medibio cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Medibio only as of the date of this presentation. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made.

Medibio will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

	Shares	Options	Description
Currently Issued	90.1 million	14,863,342 (Ex $0.10 unlisted) 6,667,000 (Ex $0.30 unlisted)	
Vendor Milestone 1	6,000,000	nil	(VALIDATION)
Vendor Milestone 2	6,000,000	nil	(ALGORITHIM)
Vendor Milestone 3	6,000,000	nil	
ALL MILESTONES ACHIEVED	**108.1 million**	**21.7 million**	
Escrowed Shares	23,929,979		escrowed for 12 months
Board/Management Ownership	38,671,470		includes escrowed shares above
Top 20	63,330,745		(70.3%)

Medibio LIMITED

Advisory Board

DR JAMES CAMPELL
Non Exec Director

KRIS KNAUER
Chief Executive Officer

CHRIS INDERMAUR
Chairman

DR MICHAEL PLAYER
COO

DR MATT MESNIK
CMO

STEVEN STAPELBERG
VP eHealth

SEAN MATHIESON
Chief Innovation Officer

ROBERT LEES
CFO & Co Sec

DR MATT FLAX
Head of Algorithm Development Team

CLAUDE SOLITARIO
Head Sales

PROF FRANK PREDERGAST
(Eli Lilly Company)

STEPHEN PEARCE
(Lions Eye Institute)

PROF HANS STAMPFER
(Inventor)

DR STEPHEN ADDIS
(Inventor)